Article Text

PDF
SAT0465 The Myositis Disease Activity Assessment Tool and the Printo Criteria for Clinically Inactive Disease Applied after Long-Term Follow-Up in Juvenile Onset Dermatomyositis.
  1. H. Sanner1,
  2. I. Sjaastad2,
  3. B. Flatø1
  1. 1Dept Rheumatology, Oslo University Hospital
  2. 2Dept Cardiology, Oslo University Hospital-Ullevål, Oslo, Norway

Abstract

Background There is limited knowledge about persistent disease activity and frequency of inactive disease in Juvenile Dermatomyositis (JDM) patients after long-term follow-up.

Objectives To apply the Myositis Disease Activity Assessment Tool (MDAAT) and Pediatric Rheumatology International Trials Organization (PRINTO) criteria for inactive disease in JDM patients after long-term follow-up, and to examine associations between clinically inactive disease, MDAAT, and other validated disease activity measures.

Methods Inclusion criteria were probable or definitive Dermatomyositis (Bohan/Peter criteria), disease onset before 18 years and minimum 2 years disease duration. A retrospective inception cohort of 60 JDM patients (60% female) was clinically examined median 16.8 years (range 2–38 years) after disease onset. The cohort was divided in patients with inactive (JDM-inactive) and active disease (JDM-active) by the PRINTO criteria; at least three of four of: CK≤150, Child Myositis Assessment Scale (CMAS) ≥ 48, Manual Muscle Test (MMT) ≥ 78 and physician global disease activity (PhyGloVAS) ≤ 0.2. Disease activity was also measured by MDAAT (Myositis Intention-to-Treat Activity Index (MITAX) and the Myositis Disease Activity Assessment Visual Analog Scales (MYOACT)), Disease Activity Score (DAS), patient/parent overall disease activity (PtsGloVAS) and child-HAQ/HAQ.

Results Thirty patients (50%) had inactive disease (15 female); disease duration in JDM-active and JDM-inactive were comparable. All variables included in the PRINTO composite score for inactive disease clearly differed between the two groups (P`s < 0.001), except for CK which was similar (P=0.660). At follow-up, 18/60 (30%) used at least one anti-inflammatory drug; 14 of these were JDM-active. Of JDM-inactive patients, 4/30 patients were inactive on medication and 26/30 inactive off medication. By MYOACT, disease activity was most common in the skin (58%), skeletal (28%) and constitutional and muscle domains (both 18%). MYOACT global and MYOACT extramuscular both showed a strong correlation with DAS and PhyGloVAS (rs`s ≥ 0.85) and a moderate correlation with PtsGloVAS, CMAS, MMT, and CHAQ/HAQ (rs`s 0.32-0.49).

Conclusions Median 16.8 years after disease onset, 50% of JDM patients had clinically inactive disease which was highly associated with low disease activity measured by MDAAT and DAS.

Disclosure of Interest None Declared

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.